10.6084/m9.figshare.4626262.v1
Abad S.
Abad
S.
Vega A.
Vega
A.
Hernández E.
Hernández
E.
Mérida E.
Mérida
E.
de Sequera P.
de Sequera P.
Albalate M.
Albalate
M.
Macías N.
Macías
N.
Milla M.
Milla
M.
López-Gómez J.M.
López-Gómez
J.M.
PowerPoint Slides for: Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4
Karger Publishers
2017
Hepatitis C virus infection
Direct-acting antivirals
Hemodialysis
Ribavirin
2017-02-07 15:29:10
Dataset
https://karger.figshare.com/articles/dataset/PowerPoint_Slides_for_Universal_Sustained_Viral_Response_to_the_Combination_of_Ombitasvir_Paritaprevir_Ritonavir_and_Dasabuvir_with_without_Ribavirin_in_Patients_on_Hemodialysis_Infected_with_Hepatitis_C_Virus_Genotypes_1_and_4/4626262
<p><b><i>Background:</i></b> Hepatitis C virus (HCV) infection is highly
prevalent among patients on hemodialysis (HD) and is associated with
poor prognosis. Treatment with interferon and ribavirin is poorly
tolerated, and few data are available on the impact of new direct-acting
antivirals (DAAs). This study was intended to analyze the efficacy and
safety of treatment with a combination of
ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin
in HCV-infected patients on HD from 3 hospitals. <b><i>Methods:</i></b>
This is a multicentric study. We analyze the clinical course of all
patients on HD with HCV infection who had been treated with the
combination of ombitasvir/paritaprevir/ritonavir and dasabuvir in 3
hospitals in Madrid, Spain. All patients under treatment had undergone
Transient elastography (FibroScan®) and HCV RNA (PCR) and HCV genotype
were determined simultaneously. <b><i>Results:</i></b> Thirty-five
patients aged 53.3 ± 8.9 years (68.6% males) and with genotypes 1 and 4
were treated with the DAA regimen, and 17 were also given ribavirin. The
most common etiology was glomerular disease. Sustained viral response
was achieved in 100% of patients. Adverse effects were negligible, and
no patient had to discontinue treatment. The most significant side
effect was anemia, which led to a significant increase in the dose of
erythropoiesis-stimulating agents. Anemia was more marked in patients
receiving ribavirin. No patients required transfusions. <b><i>Conclusion:</i></b>
A combination of ombitasvir/paritaprevir/ritonavir and dasabuvir
with/without ribavirin for the treatment of HCV in patients on HD is
highly effective and causes minimal side effects. This regimen
represents a major advance in disease management. A considerable
improvement in prognosis seems likely.</p>